Evolution of patient demographics, baseline clinical characteristics and outcomes in Phase 3 trials of biologics (TNFi, IL12/23i, IL17i, IL23i), PDE4i and TYK2i for psoriasis
Abstract Background Psoriasis, a common chronic inflammatory skin disease with major impact on quality of life, is associated with several comorbidities. A better understanding of the pathogenesis of psoriasis has led to the development and approval of new therapeutic strategies such as biologics of...
| Huvudupphovsmän: | , , , , |
|---|---|
| Materialtyp: | Artikel |
| Språk: | English |
| Publicerad: |
Wiley
2024-06-01
|
| Serie: | JEADV Clinical Practice |
| Ämnen: | |
| Länkar: | https://doi.org/10.1002/jvc2.355 |